Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24723682 | 1.00 | HRH3 (0.48) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL20850661 | 0.98 | HRH3 (0.44) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL15363087 | 0.88 | HRH3 (0.41) | HRH3MAPTCYP1A2TSHR | |
| SCHEMBL21348734 | 0.86 | HRH3 (0.50) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL19185679 | 0.85 | CARM1 (0.38) | HRH3MAPTTSHR | |
| SCHEMBL21981137 | 0.84 | PAOX (0.39) | MAPTTSHR | |
| SCHEMBL19144698 | 0.84 | HRH3 (0.43) | HRH3 | |
| SCHEMBL19928707 | 0.84 | TSHR (0.38) | MAPK1SMN1; SMN2TSHR | |
| SCHEMBL15363020 | 0.84 | HRH3 (0.43) | HRH3 | |
| SCHEMBL20332097 | 0.83 | HRH3 (0.46) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | UNIV DREXEL (US) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | RAD52, RECQL, RAD50 | HRH3 2354/4885MAPT 3228/4885CYP1A2 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.